Our mission is to detect cancer early, when it can be cured.

GRAIL

About GRAIL, LLC

GRAIL, LLC, is a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection.

The company is made up of scientists, engineers, and physicians focused on using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer and data science to overcome one of healthcare's greatest challenges.

In September 2020, GRAIL entered into an agreement to be acquired by Illumina with the goal of accelerating the commercialization and adoption of its transformative multi-cancer early detection technologies. The acquisition is now subject to standard regulatory reviews.

Pioneering New Technologies for Early Cancer Detection

GRAIL's multi-cancer early detection test, Galleri®, is designed to detect the presence of cancer and predict the location of the cancer signal in the body, such as the lungs or the colon. An earlier version of Galleri demonstrated the ability to detect and identify more than 50 types of cancers – over 45 of which lack recommended screening today – with a very low false positive rate, all through a single blood draw.

Earlier cancer detection has the potential to reduce the human and economic toll of cancer by enabling treatment that's more successful and less costly. Our model estimates that by adding Galleri to existing screening tests, there is the potential to detect nearly 70% of cancers resulting in death within five years at an earlier stage, which would translate to the potential to avert 39% of the deaths expected if not for early detection by Galleri.

In addition, GRAIL is developing a diagnostic aid for cancer test (DAC) meant to accelerate the diagnosis for patients for whom there is a clinical suspicion of cancer, and a minimal residual disease (MRD) test designed to enable blood-based detection with or without tissue, as well as other post-diagnostic applications.

Fast Facts

2016
Year founded

——

Menlo Park, CA
Headquarters

——

Locations in Washington, D.C., North Carolina and the UK

——

850+
Number of employees

Partnerships

Working with leading academic cancer institutions and large community networks, we have taken a rigorous approach to the design and implementation of our clinical programs.